Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN101 in Chronic Graft Versus Host Disease
NCT04930562Phase 2Completed
- Sponsor
- BioNova Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belumosudil in chronic graft-versus-host disease (cGVHD), sponsored by BioNova Pharmaceuticals. Primary endpoint: Overall Response Rate at 12 months. Started Apr 2021; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT04930562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930562.